BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

...Renard as CBO. Bernal was director of strategic marketing and corporate communications, business development of Adocia S.A....
BioCentury | Aug 23, 2019
Company News

Aug. 23 Company Quick Takes: Amgen-Alexion, Lilly-Adocia, Gilead-Galapagos

...barbs in the U.S.-China trade war. Tribunal rules in Lilly's favor in arbitration with Adocia Adocia S.A....
...Adocia said the outcome does not affect a 2018 decision by the tribunal to award Adocia...
..."Gilead's $5.1B Galapagos Deal Threads the Needle Between M&A and Licensing" ). Elizabeth S. Eaton, Staff Writer Adocia S.A. Alexion...
BioCentury | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

...Sarah Gould as chief development officer. She was non-clinical director for pharmacology and toxicology at Adocia S.A....
BioCentury | Apr 27, 2018
Company News

Tonghua gets rights to two insulin products from Adocia

...BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia...
...in milestones, plus double-digit royalties. Additionally, Tonghua Dongbao will reimburse Adocia for undisclosed R&D expenses. Adocia S.A....
BioCentury | Aug 1, 2017
Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

...Biotech Europe subsidiary. Inflammation company AnaptysBio Inc. (NASDAQ:ANAB) said CSO Matthew Moyle resigned. Diabetes company Adocia S.A....
BioCentury | Jul 28, 2017
Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

...In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous...
...January, Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned worldwide rights to Adocia’s...
...insulin lispro using BioChaperone polymer technology. Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) markets Fiasp and Novolog. Adocia S.A....
BioCentury | Jun 9, 2017
Clinical News

Adocia starts Phase I trial of BioChaperone glucagon to treat Type I diabetes

...a stable aqueous formulation of recombinant human glucagon produced using the Adocia's BioChaperone polymer technology. Adocia S.A....
...Type I diabetes Endpoint: Safety; pharmacokinetics Status: Phase I started Milestone: Phase I data (4Q17) Julian Zhu Adocia S.A. BioChaperone...
BioCentury | Feb 3, 2017
Company News

Adocia, Lilly deal

...Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type...
...for exclusive, worldwide rights to the ultra-fast-acting formulation of insulin lispro using BioChaperone polymer technology. Adocia...
...Adocia S.A. (Euronext:ADOC), Lyon, France Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic Chris Lieu BioChaperone Lispro Adocia S.A. Eli...
BioCentury | Jan 27, 2017
Company News

Lilly returns diabetes candidate to Adocia

...it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's...
...formulation of insulin lispro using BioChaperone polymer technology (see BioCentury Extra, Dec. 19, 2014) . Adocia...
...July at the the American Diabetes Association Scientific Sessions meeting in San Diego. In 2013, Adocia...
BioCentury | Oct 10, 2016
Clinical News

BioChaperone insulin combo: Phase Ib started

...lispro plus subcutaneous Lantus insulin glargine and vs. subcutaneous Humalog Mix25 insulin lispro/insulin lispro protamine. Adocia S.A....
Items per page:
1 - 10 of 75
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

...Renard as CBO. Bernal was director of strategic marketing and corporate communications, business development of Adocia S.A....
BioCentury | Aug 23, 2019
Company News

Aug. 23 Company Quick Takes: Amgen-Alexion, Lilly-Adocia, Gilead-Galapagos

...barbs in the U.S.-China trade war. Tribunal rules in Lilly's favor in arbitration with Adocia Adocia S.A....
...Adocia said the outcome does not affect a 2018 decision by the tribunal to award Adocia...
..."Gilead's $5.1B Galapagos Deal Threads the Needle Between M&A and Licensing" ). Elizabeth S. Eaton, Staff Writer Adocia S.A. Alexion...
BioCentury | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

...Sarah Gould as chief development officer. She was non-clinical director for pharmacology and toxicology at Adocia S.A....
BioCentury | Apr 27, 2018
Company News

Tonghua gets rights to two insulin products from Adocia

...BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia...
...in milestones, plus double-digit royalties. Additionally, Tonghua Dongbao will reimburse Adocia for undisclosed R&D expenses. Adocia S.A....
BioCentury | Aug 1, 2017
Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

...Biotech Europe subsidiary. Inflammation company AnaptysBio Inc. (NASDAQ:ANAB) said CSO Matthew Moyle resigned. Diabetes company Adocia S.A....
BioCentury | Jul 28, 2017
Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

...In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous...
...January, Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned worldwide rights to Adocia’s...
...insulin lispro using BioChaperone polymer technology. Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) markets Fiasp and Novolog. Adocia S.A....
BioCentury | Jun 9, 2017
Clinical News

Adocia starts Phase I trial of BioChaperone glucagon to treat Type I diabetes

...a stable aqueous formulation of recombinant human glucagon produced using the Adocia's BioChaperone polymer technology. Adocia S.A....
...Type I diabetes Endpoint: Safety; pharmacokinetics Status: Phase I started Milestone: Phase I data (4Q17) Julian Zhu Adocia S.A. BioChaperone...
BioCentury | Feb 3, 2017
Company News

Adocia, Lilly deal

...Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type...
...for exclusive, worldwide rights to the ultra-fast-acting formulation of insulin lispro using BioChaperone polymer technology. Adocia...
...Adocia S.A. (Euronext:ADOC), Lyon, France Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic Chris Lieu BioChaperone Lispro Adocia S.A. Eli...
BioCentury | Jan 27, 2017
Company News

Lilly returns diabetes candidate to Adocia

...it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's...
...formulation of insulin lispro using BioChaperone polymer technology (see BioCentury Extra, Dec. 19, 2014) . Adocia...
...July at the the American Diabetes Association Scientific Sessions meeting in San Diego. In 2013, Adocia...
BioCentury | Oct 10, 2016
Clinical News

BioChaperone insulin combo: Phase Ib started

...lispro plus subcutaneous Lantus insulin glargine and vs. subcutaneous Humalog Mix25 insulin lispro/insulin lispro protamine. Adocia S.A....
Items per page:
1 - 10 of 75